Want to see ZYBT full AI Analyst Report?
ZYBT Stock Chart & Stats
$1.13
--
Market closed
$1.13
--
Day’s Range― - ―
52-Week Range$0.62 - $8.01
Previous CloseN/A
VolumeN/A
Average Volume (3M)26.60K
Market Cap
$51.42M
Enterprise Value$10.00T>
Total Cash (Recent Filing)$51.89M
Total Debt (Recent Filing)$75.08M
Price to Earnings (P/E)―
Beta-0.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume19,839
30 Day Avg. Volume26,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.52
Price to Sales (P/S)3.27
P/FCF Ratio541.63
Enterprise Value/Market Cap5.31M
Enterprise Value/Revenue3.41M
Enterprise Value/Gross Profit41.08M
Enterprise Value/Ebitda-6.60M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate leverage and a sizable equity base provide some capacity to absorb operating volatility and fund priorities without relying excessively on debt. This balance-sheet cushion supports financial resilience over the next several quarters, although sustained losses could weaken that protection.
Integrated Animal Health PlatformA broad veterinary vaccine portfolio combined with vertically integrated, GMP-compliant facilities can support product control, regulatory consistency, and market reach. Its presence across China and selected international markets provides an established platform for rebuilding demand over time.
Positive Operating Cash FlowPositive operating cash flow during a loss year indicates that the business still generated cash from operations rather than consuming cash entirely. Although the amount declined sharply, this provides a base for stabilization if revenue and operating performance recover.
Bears Say
Revenue And Profitability CollapseThe sharp revenue contraction and transition from positive profitability to a very large net loss point to a fundamental deterioration in demand, pricing, or cost control. Unless reversed, this weak earnings base can constrain investment, capital flexibility, and future growth.
Thin And Volatile Cash ConversionCash generation has weakened materially alongside the earnings decline, leaving little free cash flow after operating needs and investment. Thin conversion reduces the company’s ability to self-fund expansion, strengthen the balance sheet, or withstand further operating setbacks.
Recent Nasdaq Bid Compliance RiskAlthough compliance was restored, the recent minimum-bid breach demonstrates a meaningful listing risk that could recur if business weakness affects investor confidence. Continued exchange compliance remains important for market access, credibility, and shareholder liquidity.
Zhengye Biotechnology Holding Ltd. News
ZYBT FAQ
What was Zhengye Biotechnology Holding Ltd.’s price range in the past 12 months?
Zhengye Biotechnology Holding Ltd. lowest stock price was $0.61 and its highest was $8.01 in the past 12 months.
What is Zhengye Biotechnology Holding Ltd.’s market cap?
Zhengye Biotechnology Holding Ltd.’s market cap is $51.42M.
When is Zhengye Biotechnology Holding Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhengye Biotechnology Holding Ltd.’s earnings last quarter?
Currently, no data Available
Is Zhengye Biotechnology Holding Ltd. overvalued?
According to Wall Street analysts Zhengye Biotechnology Holding Ltd.’s price is currently Overvalued.
Does Zhengye Biotechnology Holding Ltd. pay dividends?
Zhengye Biotechnology Holding Ltd. does not currently pay dividends.
What is Zhengye Biotechnology Holding Ltd.’s EPS estimate?
Zhengye Biotechnology Holding Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhengye Biotechnology Holding Ltd. have?
Zhengye Biotechnology Holding Ltd. has 10,965,000 shares outstanding.
What happened to Zhengye Biotechnology Holding Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhengye Biotechnology Holding Ltd.?
Currently, no hedge funds are holding shares in ZYBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhengye Biotechnology Holding Ltd. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Technical Analysis
China Pharma Holdings
―
Aytu BioScience
―
China SXT Pharmaceuticals
―
Qilian International Holding Group Limited
―
Universe Pharmaceuticals
―
Ownership Overview
―
Insiders
0.27% Mutual Funds
0.12% Other Institutional Investors
99.62% Public Companies and
Individual Investors